Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for TILDRAKIZUMAB
- Psoriatic Immune Response to Tildrakizumab
- A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis
- Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
- Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo
- The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid
- Abiraterone Acetate in Combination With Tildrakizumab
- Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
- Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
- Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
- MIcrovascular dysfuNction In Moderate-severe Psoriasis
- Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy
- Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)
- Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease
- A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
- Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis
- Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
- A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis
- Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.
- Efficacy and Safety Study of SUNPG1622
- Efficacy and Safety Study of SUNPG1623
- A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
- A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)
- A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)
Clinical trials list
click for details